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In vivo pharmacokinetics studies have shown that the proline-rich antimicrobial peptide,
A3-APO, which is a discontinuous dimer of the peptide, Chex1-Arg20, undergoes
degradation to small fragments at positions Pro6-Arg7 and Val19-Arg20. With the aim
of minimizing or abolishing this degradation, a series of Chex1-Arg20 analogs were
prepared via Fmoc/tBu solid phase peptide synthesis with D-arginine or, in some cases,
peptide backbone Nα-methylated arginine, substitution at these sites. All the peptides
were tested for antibacterial activity against the Gram-negative bacterium Klebsiella
pneumoniae. The resulting activity of position-7 substitution of Chex1-Arg20 analogs
showed that arginine-7 is a crucial residue for maintaining activity against K. pneumoniae.
However, arginine-20 substitution had a much less deleterious effect on the antibacterial
activity of the peptide. Moreover, none of these peptides displayed any cytotoxicity to
HEK and H-4-II-E mammalian cells. These results will aid the development of more
effective and stable PrAMPs via judicious amino acid substitutions.
Keywords: A3-APO, Chex1-Arg20, D-arginine, Gram-negative bacteria,K. pneumoniae, backboneNα-methylation,
proline-rich antimicrobial peptide
INTRODUCTION
The increasing widespread onset of bacterial multi-drug resistance, associated with major clinical
pathogenic infections, has resulted in calls for the development new antimicrobial agents
(Laxminarayan et al., 2013). Due to their broad-spectrum activities andmulti-modal actions against
pathogens, antimicrobial peptides (AMPs) (also known host-defense peptides), are considered
as attractive potential candidates for new antibiotics (Hilchie et al., 2013; Lam et al., 2016).
Importantly, these peptides have also attracted considerable attention as alternative means of plant
disease control to conventional treatments that are polluting and hazardous to both human health
and the environment (Datta et al., 2015, 2016). Among these peptides, the class of proline-rich
AMPs (PrAMPs) possess a unique multi-modal mechanism of action against pathogens and display
potent activity against Gram-negative bacteria (Otvos et al., 2005; Czihal et al., 2012; Guida et al.,
2015). These actions include membrane rupture (Li et al., 2014), inhibition of the bacterial shock
heat protein DnaK (Kragol et al., 2001; Scocchi et al., 2009), blockade of bacterial ribosomal protein
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expression (Krizsan et al., 2014; Roy et al., 2015; Seefeldt et al.,
2015, 2016; Goldbach et al., 2016), and immunostimulatory
activity (Ostorhazi et al., 2011). Recently, a PrAMP and other
AMPs were impregnated into nanofibers or hydrogels for the
potential treatment of skin injuries in general and battlefield
burns (Mateescu et al., 2015; Sebe et al., 2016).
The peptide, Chex1-Arg20, was de novo designed based
on native PrAMPs with additional sequence optimization to
enhance bacterial membrane penetration (Otvos et al., 2005;
Noto et al., 2008; Rozgonyi et al., 2009). It has been shown
that multimerization of Chex-Arg20 to a discontinuous dimer or
tetramer results in an alteration of its mechanism of interaction
with the Escherichia coli membrane (Li et al., 2015a). These
observations were further confirmed on investigation of Chex1-
Arg20 and its multimers with model membranes (Li et al.,
2016). Additionally, specific C-terminal chemical modifications
of the Chex1-Arg20 monomer were shown to expand both its
activity and spectrum of Gram-negative bacterial action (Li et al.,
2015b). These observations led to the development of a series
of tetrameric Chex1-Arg20 bearing a C-terminal hydrazide that
were shown to possess a more compact structure and potent and
broadened activity against Gram-negative nosocomial pathogens
(Li et al., 2017).
The discontinuous dimer of Chex1-Arg20, A3-APO, was
shown in in vivo pharmacokinetic studies to undergo degradation
at positions Pro6-Arg7 and Val19-Arg20, as well as to
produce the major metabolite, Chex1-Arg20 (Noto et al.,
2008). A key goal is to undertake chemical modifications
at these labile sites to confer significant improvement in
peptide stability in serum without undue effect on their
activity (Otvos and Wade, 2014). D-amino acid substitution in
AMPs has previously been shown to be a successful strategy
(Hong et al., 1999). This suggests that partial D-amino acid
substitutions within Chex1-Arg20 might be a useful means to
improve its activity and stability. Furthermore, backbone N-
methylation of peptide bonds can also confer high stability
against proteases and improved pharmacological bioavailability
(Di Gioia et al., 2016). Therefore, we undertook to incorporate
the unnatural D-amino acid and Nα-methyl-amino acid into
two key points within the peptide sequence to determine
the effect on activity against Gram-negative bacterium K.
pneumoniae.
MATERIALS AND METHODS
Materials
Nine-Fluorenylmethoxylcarbonyl (Fmoc)-L-amino acids, 2-
(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylamonium
hexafluorophosphate (HCTU), and 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid (HATU)
were from GL Biochem (Shanghai, China). TentaGel-MB-
RAM-resin was from Rapp Polymere (Tubingen, Germany).
Nα-Fmoc-Nα-methyl-L-arginine(Nω-Pbf), and Nα-Fmoc-
D-arginine(D-Pbf) were purchased from Novabiochem
(Sydney, Australia). N,N-Diisopropylethylamine (DIPEA),
dimethylformamide (DMF), and trifluoroacetic acid (TFA)
were obtained from Auspep (Melbourne, Australia). Piperidine,
triisopropylsilane (TIPS), anisole, and acetonitrile (CH3CN)
were all obtained from Sigma (Sydney, Australia).
Peptide Synthesis
The peptides were synthesized by Fmoc/tBu solid-phase methods
(Fields and Noble, 1990) using a CEM Liberty microwave-
assisted synthesizer and TentaGel-MB-RAM-resin as previously
described (Li et al., 2015a). Standard Fmoc-chemistry was used
throughout with a 4-fold molar excess of the Fmoc-protected
amino acids in the presence of 4-fold HCTU and 8-fold DIPEA.
For the arginine derivative substitution, 1.5-fold of amino acid
coupling was used together with 1.5 equivalents HATU and
3 equivalents of DIPEA. After synthesis, the peptides were
cleaved from the solid support resin with TFA in the presence
of anisole and TIPS as scavengers (95:3:2, v/v) for 2 h at
room temperature. After filtration to remove the resin, the
filtrate was concentrated under a stream of nitrogen and the
peptide products were precipitated in ice-cold diethyl ether
and washed three times. The peptides were then purified by
reversed-phase high performance liquid chromatography (RP-
HPLC) in water and acetonitrile containing 0.1% TFA using
a gradient of 10–40% (acetonitrile) in 40 min. Due to the
variation in hydrophobicity between the different analogs, the
final products were characterized by RP-HPLC using a gradient
of either 0–40% (acetonitrile) in 40 min or 10–40% (acetonitrile)
in 30 min. Matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) was also used for
characterization.
Antibacterial Assay
An antibacterial assay was undertaken to determine the minimal
inhibitory concentration (MIC) as described previously (Li
et al., 2015b). The Gram-negative nosocomial bacterium,
K. pneumoniae ATCC13883, was selected for testing the
antibacterial activities of the Chex1-Arg20 analogs using 2.5
× 105 cells/ml in Mueller Hinton broth (MHB) at 37◦C
immediately prior to the determination of MIC.
Cell Proliferation Test
The proliferation of HEK-293 (ATCC R© CRL-1573TM) and H-4-
II-E (ATCC R© CRL-1548TM) cells were tested with the Chex1-
Arg20 analogs using the CellTiter 96 AQueous Non-Radioactive
TABLE 1 | Primary structure of Chex1-Arg20 analogs used in this report.
No Name Sequence* MWcal MWfd
1 Chex1-Arg20 Chex-RPDKPRPYLPRPRPPRPVR-NH2 2475.0 2476.8
2 DR7 Chex-RPDKP r PYLPRPRPPRPVR-NH2 2474.9 2474.8
3 DR7(1–19) RPDKP r PYLPRPRPPRPV-NH2 2318.8 2319.3
4 DR7(7–19) r PYLPRPRPPRPV-NH2 1600.1 1603.0
5 Chex1-Val19 Chex-RPDKP r PYLPRPRPPRPV-NH2 2318.8 2319.2
6 DR20 Chex-RPDKPRPYLPRPRPPRPV r-NH2 2474.9 2475.2
7 mR20 Chex-RPDKPRPYLPRPRPPRPVmR-NH2 2489.0 2488.9
8 reverse Chex-RVPRPPRPRPLYPRPKDPR-NH2 2475.0 2478.0
*Abbreviations: r, D-Arg; mR, Nα-methyl-arginine; MWcal , calculated mass; MWfd , found
mass in MALDI.
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Cell Proliferation Assay (Promega) as described previously (Li
et al., 2015b).
RESULTS AND DISCUSSION
Peptide Preparation
Peptide 1was prepared as described in a previous report (Li et al.,
2015b) and 2–8 were prepared on TentaGel-MB-RAM-resin via
standard Fmoc/tBu solid-phase methods. Unnatural amino acid
incorporation was achieved in presence of HATU instead of
HCTU (Table 1) which produced better quality products. Each
Chex1-Arg20 analog was obtained in an overall yield of ca.
∼15% relative to the crude cleaved starting material. Each analog
was then subjected to comprehensive chemical characterization
including analytical RP-HPLC and MALDI-TOF MS to confirm
their purity (Figure 1).
Antibacterial Activity
Each Chex1-Arg20 analog was assayed against the nosocomial
Gram-negative bacterium K. pneumoniae ATCC 13883. The
FIGURE 1 | RP-HPLC and MALDI-TOF/ESI MS for peptide analogs 2–8, respectively: (A) 2 , DR7; (B) 3, DR7(1–19); (C) 4, DR7(7–19); (D) 5, Chex1-Val19; (E)
6, DR20; (F) 7, mR20; (G) 8, reverse. Analysis condition: Phenomenex C18 column (WIDEPORE 3.6 µ XB-C18, 150 × 4.6 nm); buffer A, 0.1% aq. TFA; buffer B,
0.1% TFA in acetonitrile; gradient, buffer B 0–40% in 40 min for (A) 2 and (B) 3, and 10–40% in 30 min for (C) 4–(G) 8.
TABLE 2 | Antibacterial activity, MIC (µM), of Chex1-Arg20 analogs against Gram-negative pathogen K. pneumoniae ATCC 13883.
Bacterium 1* 2 3 4 5 6 7 8
K. pneumoniae 0.8 ± 0.1* >100 >100 >100 36.1 ± 0.6 11.8 ± 0.1 14.5 ± 0.1 >100
*The activity of analog 1 was previously reported (Li et al., 2015b).
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TABLE 3 | Cytoxocity (µM) of Chex1-Arg20 analogs against mammalian
cell lines, H-4-II-E (ATCC® CRL-1573TM) and H-4-II-E (ATCC®
CRL-1548TM), in which >100 µM or >50 indicated there was no
cytotoxicity at the highest tested concentration 100 µM or 50 µM.
Analogue H-4-II-E cell HEK cell
1 >100 µM >100 µM
2 >100 µM >100 µM
3 >100 µM >100 µM
4 >100 µM >100 µM
5 >100 µM >100 µM
6 >100 µM >100 µM
7 >100 µM >100 µM
8 >100 µM >100 µM
results are shown in Table 2 in comparison with analog 1, Chex1-
Arg20. Replacement of arginine at position 7 with the D-form
(analog 2) resulted in substantial loss of activity. This highlighted
the importance of arginine-7 and its native L-configuration for
characteristic antimicrobial activity. Curiously, truncation of the
C-terminal Arg20 from analog 2 to produce analog 5 partially
restored activity. Compared with analog 5, the N-terminal
shortened analogs 2–4 containing a D-arginine substitution at
position 7 showed a drastic loss of activity against this pathogen
in MHB. In contrast, replacement of position Arg20 with either
the D-arginine or Nα-methylated-arginine (analogs 6–7) led
to a maintenance of significant activity of the native Chex1-
Arg20 which indicates that this residue is more tolerant to
modification to improve its in vivo stability to degradation.
Finally, the reverse sequence (analog 8) was also evaluated and,
as expected, it showed no activity against K. pneumoniae which
confirmed the necessity of the native sequence for antibacterial
action.
Cytotoxicity
In vitro cytotoxicity was also measured via the Promega
CellTiter 96 AqueousNon-Radioactive Cell Proliferation Assay
(Li et al., 2015a) using the mammalian cell lines HEK-293
(ATCC CRL 1573) and H-4-II-E (ATCC CRL-1548). None of
the Chex1-Arg20 analogs showed any toxicity against either
mammalian cell line at the highest tested concentration (100µM)
(Table 3).
CONCLUSIONS
In summary, a series of D-amino acid substituted analogs of
the PrAMP, Chex1-Arg20, were prepared by standard Fmoc/tBu
solid phase peptide synthesis. These analogs were tested against
the Gram-negative bacterium K. pneumoniae for antibacterial
activity. In this study, the activity of D-arginine Chex1-Arg20
showed the replacement of arginine at position seven led to
drastic loss of activity. The short fragments, Arg2-Val19 and
Arg7-Val19, also displayed no antibacterial activity. However,
substitution at position 20 with either D-arginine or Nα-methyl-
arginine did not greatly affect the activity against K. pneumoniae.
Moreover, none of these peptides showed any cytotoxicity to
HEK and H-4-II-E mammalian cells. Such findings will assist
the development of more effective and stable Chex1-Arg20 and
A3-APO analogs with further substitution at position 20.
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